RxDoctor Payments Data

Tze Ip, MD

Cardiovascular Disease · Mission Viejo, CANPI 1316924947

Payments from drug & device makers

$1,224in general payments, 2019–2025

Across 59 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$259
  • Amgen$247
  • Pfizer$211
  • Boston Scientific$190
  • Cathworks, Inc.$91
  • Novartis$63
  • plus $165 from 5 others

What the payments were for

  • Food & beverage$1,224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,224 in reported general payments places this provider in the 35th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$408,275
Medicare patients
2,231
Services billed
6,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$313,424
EntrestoSacubitril/Valsartan161$173,047
XareltoRivaroxaban75$48,742
Repatha SureclickEvolocumab42$35,578
FarxigaDapagliflozin Propanediol40$31,186
JardianceEmpagliflozin18$21,500
BrilintaTicagrelor25$17,068
DiovanValsartan12$12,036
Rosuvastatin Calcium597$9,436
Ezetimibe228$6,327
Repatha SyringeEvolocumab12$6,117
Metoprolol Succinate325$4,887
Valsartan238$3,881
Prasugrel Hcl27$3,660
Carvedilol375$3,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$313,424339 claims
NovartisEntresto, Diovan$63$185,083173 claims
Boehringer IngelheimJardiance$17$21,50018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →